Erythropoiesis and estimated fluid volume regulation following initiation of ipragliflozin treatment in patients with type 2 diabetes mellitus and chronic kidney disease: A post‐hoc analysis of the PROCEED trial

Documents similaires

• Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study
  par: Tatsuhiko Azegami, et autres
  Publié: (2025)
• Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan
  par: Yuichiro Yano, et autres
  Publié: (2025)
• Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial
  par: Caren Sourij, et autres
  Publié: (2024)
• Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial
  par: Ying Zhu, et autres
  Publié: (2025)
• Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
  par: Jingyu Wang, et autres
  Publié: (2024)